Drug Profile
Inhaled liposomal tobramycin - Axentis Pharma AG
Alternative Names: ARB-CF0223; Fluidosome tobramycin; Fluidosomes-tobramycinLatest Information Update: 23 Dec 2021
Price :
$50
*
At a glance
- Originator aRigen
- Developer Axentis Pharma
- Class Aminoglycosides; Anti-infectives; Antibacterials; Antibronchitics; Small molecules
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Cystic fibrosis-associated respiratory tract infections
Most Recent Events
- 07 Aug 2015 Phase-II development is ongoing in Europe
- 16 Jul 2009 Tobramycin liposomal receives orphan drug status for Cystic fibrosis-associated respiratory tract infections caused by Burkholderia cepacia in USA
- 04 Sep 2008 Phase-IIa clinical trials in Cystic fibrosis-associated respiratory tract infections in Europe (Inhalation)